drugset / Trial / NCT02177435

Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate Hypertension

NCT02177435

Phase 3 Completed 491 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to demonstrate that a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide (HCTZ) 12.5 mg (FDC 80/12.5) is superior to telmisartan 80 mg (Telm 80) alone in patients who failed to respond adequately to Telm 80 monotherapy in lowering seated trough diastolic blood pressure (DBP) after eight weeks of treatment.

Timeline

Start
1999-02
Primary completion
1999-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrochlorothiazide Unknown 12.5 mg
Subject Telmisartan Other / unclassified 80 mg

Indications